Clinical Trial Update: Safety, Tolerability, and Immunogenicity Study of Homologous Ad26 Mosaic Vector Vaccine Regimens or Heterologous Ad26 Mosaic and MVA Mosaic Vector Vaccine Regimens With Glycoprotein 140 (gp140) for Human Immunodeficiency Virus (HIV) Prevention [Phase 1, Phase 2]

View source ↗

Summary

An update on Phase 1/2 trials assessing safety, tolerability, and immunogenicity of HIV prevention vaccines using Ad26 mosaic vectors (homologous) or a heterolo…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Ad26 mosaic vector vaccine regimens (gp140) (Ad26 mosaic vector vaccine)
• MVA mosaic vector vaccine regimens with gp140 (MVA mosaic vector vaccine)

Snippet

Sponsor: Janssen Vaccines & Prevention B.V. | Conditions: Healthy | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2020-11-04